JP2025505652A5 - - Google Patents

Info

Publication number
JP2025505652A5
JP2025505652A5 JP2024546456A JP2024546456A JP2025505652A5 JP 2025505652 A5 JP2025505652 A5 JP 2025505652A5 JP 2024546456 A JP2024546456 A JP 2024546456A JP 2024546456 A JP2024546456 A JP 2024546456A JP 2025505652 A5 JP2025505652 A5 JP 2025505652A5
Authority
JP
Japan
Prior art keywords
cycles
combination drug
antibody
approximately
drug according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024546456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025505652A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2023/050151 external-priority patent/WO2023147673A1/en
Publication of JP2025505652A publication Critical patent/JP2025505652A/ja
Publication of JP2025505652A5 publication Critical patent/JP2025505652A5/ja
Pending legal-status Critical Current

Links

JP2024546456A 2022-02-07 2023-02-06 非小細胞肺がんの治療における使用のための併用療法 Pending JP2025505652A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263307533P 2022-02-07 2022-02-07
US63/307,533 2022-02-07
US202263333597P 2022-04-22 2022-04-22
US63/333,597 2022-04-22
PCT/CA2023/050151 WO2023147673A1 (en) 2022-02-07 2023-02-06 Combination therapy for use in treatment of non-small cell lung cancer

Publications (2)

Publication Number Publication Date
JP2025505652A JP2025505652A (ja) 2025-02-28
JP2025505652A5 true JP2025505652A5 (https=) 2026-02-13

Family

ID=87553087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024546456A Pending JP2025505652A (ja) 2022-02-07 2023-02-06 非小細胞肺がんの治療における使用のための併用療法

Country Status (9)

Country Link
US (1) US20250108110A1 (https=)
EP (1) EP4475885A4 (https=)
JP (1) JP2025505652A (https=)
KR (1) KR20240153627A (https=)
AU (1) AU2023216333A1 (https=)
CA (1) CA3243096A1 (https=)
IL (1) IL314600A (https=)
MX (1) MX2024009671A (https=)
WO (1) WO2023147673A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034462B1 (ru) * 2009-11-24 2020-02-11 Алетиа Байотерапьютикс Инк. Антикластериновые антитела и антигенсвязывающие фрагменты и их использование для уменьшения объема новообразований
US9822170B2 (en) * 2012-02-22 2017-11-21 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
CA3173786A1 (en) * 2021-04-27 2022-10-27 Mario Filion Method for allowing immune cells infiltration in tumors

Similar Documents

Publication Publication Date Title
ten Tije et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial
JP2022531408A5 (https=)
JP2023533937A5 (https=)
TWI719765B (zh) 使用包含akt抑制劑、紫杉烷及pd-l1抑制劑之組合療法之乳癌治療
Saif et al. Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature
JP2021530502A5 (https=)
JP2022548978A5 (https=)
Liu et al. Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial
JP2024521105A5 (https=)
CN109806393B (zh) 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途
JP2021523096A5 (https=)
JP2021529777A5 (https=)
JP2021531330A (ja) 組合せ療法を使用してがんを治療する方法
JP2025505652A5 (https=)
CN114159557A (zh) 一种治疗肿瘤疾病的联合用药组合物及应用
JP2022530599A5 (https=)
US20260077040A1 (en) Compositions and methods for treating advanced solid tumors
JP2022547061A5 (https=)
CN103338779B (zh) 分枝杆菌w在制备治疗癌症药物中的用途
JP2023534300A5 (https=)
CN110013552B (zh) 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途
JP2024511977A5 (https=)
Chen et al. Re-irradiation with concurrent pembrolizumab for local-regionally recurrent squamous cell carcinoma of the head and neck
Trédaniel et al. Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer
US20250019441A1 (en) Treatment of cancer with anti-ilt2 antibodies